HC Wainwright Estimates OTCMKTS:BIOVF Q2 Earnings

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) – Research analysts at HC Wainwright issued their Q2 2026 EPS estimates for shares of Swedish Orphan Biovitrum in a research note issued on Wednesday, May 6th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of $0.39 for the quarter. HC Wainwright currently has a “Buy” rating on the stock. HC Wainwright also issued estimates for Swedish Orphan Biovitrum’s Q3 2026 earnings at $0.69 EPS, Q4 2026 earnings at $0.78 EPS, FY2026 earnings at $2.26 EPS, Q1 2027 earnings at $0.69 EPS, Q2 2027 earnings at $0.66 EPS, Q3 2027 earnings at $1.09 EPS, Q4 2027 earnings at $1.07 EPS and FY2027 earnings at $3.49 EPS.

Several other analysts also recently commented on BIOVF. BNP Paribas Exane raised shares of Swedish Orphan Biovitrum to an “outperform” rating in a research report on Tuesday, February 10th. Danske cut Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, February 19th. Finally, Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Performance

Shares of BIOVF stock opened at $47.48 on Friday. The company has a market cap of $16.90 billion, a price-to-earnings ratio of 158.25 and a beta of 0.34. Swedish Orphan Biovitrum has a 52 week low of $27.06 and a 52 week high of $47.48. The company has a quick ratio of 0.59, a current ratio of 0.90 and a debt-to-equity ratio of 0.14. The firm has a 50 day moving average of $40.85 and a 200-day moving average of $37.43.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.38 by $0.07. The company had revenue of $755.76 million during the quarter, compared to the consensus estimate of $749.76 million. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 17.23%.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm?based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high?value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in?licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto?inflammatory conditions.